Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority

Pluri, Inc. announced that the Israel Innovation Authority will fund Pluri’s collaboration with the Bar-Ilan University Research and Development Company, Ltd. to support the continued development of Placental Mucosal Associated Invariant T cells for solid tumors.